OCT 26 2026
GSK — bepirovirsen $GSK
for chronic hepatitis B infection
Accepted APR 28 2026.
About
Chronic hepatitis B is a viral infection that attacks the liver and can lead to a long-term, persistent illness. Bepirovirsen is an antisense oligonucleotide designed to bind to and degrade the virus's specific genetic material (mRNA). By reducing the viral blueprint, the drug aims to lower the amount of virus in the body, which could potentially help control the chronic infection.
Pivotal trial
This study is intended to confirm the efficacy, safety, pharmacokinetic (PK) profile, and the durability of hepatitis B virus surface antigen (HBsAg) suppression observed with bepirovirsen for 24 weeks (with loading doses) as compared to the placebo arm. This study will have 4 stages: a) Double-blind treatment (bepirovirsen or placebo) for 24 weeks
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on bepirovirsen
- How Bepirovirsen Targets the Hepatitis B Viral Lifecycle - AJMC
- Bepirovirsen Induces Functional Cure in Hepatitis B - gastroendonews.com
- Hepatitis B Treatment: Bepirovirsen Shows Promise - gastroendonews.com
- Japan first approval for GSK’s bepirovirsen for CHB - pharmaphorum
- GSK Wins First Approval for Hepatitis B Drug Bepirovirsen - Healthcare Digital